Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLCL + Fg group refers to a combination wound dressing composed of electrospun poly(L-lactide-co-caprolactone) (PLCL), a biodegradable synthetic copolymer, and formulated porcine fibrinogen (Fg). This advanced wound care product is designed for topical application in the treatment of diabetic foot ulcers (DFUs). The mechanism involves providing a biocompatible scaffold that supports cell migration and tissue regeneration while the fibrinogen component aids in hemostasis and further promotes healing. In clinical trials, this combination has demonstrated beneficial effects on wound surface reduction and regulation of the wound microenvironment compared to standard alginate dressings[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PLCL + Fg group.